Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in Panc-1 cells.
Pancreatic cancer (PC)
SMAD4
apoptosis
autophagy
proscillaridin A (Pro A)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
02
03
2022
accepted:
23
06
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
ppublish
Résumé
Pancreatic cancer (PC) is a highly metastatic and lethal cancer with a very low overall 5-year survival rate. There is an urgent need for identifying new therapeutic agents for this deadly disease. Cardiac glycosides (CGs) have been traditionally used for their potent cardiovascular activities and have also recently been reported to exhibit anti-tumor effects. Proscillaridin A (Pro A), a natural CG, has been shown to display anti-tumor effects on multiple cancer types. The cytotoxic effect of Pro A on PC cells was determined using cell viability assay, colony formation assay and transwell assay Pro A inhibits the proliferation, migration and invasion of Panc-1, BxPC-3 and AsPC-1 PC cells Our findings suggest that Pro A constitutes a promising therapeutic candidate for certain types of PC.
Sections du résumé
Background
UNASSIGNED
Pancreatic cancer (PC) is a highly metastatic and lethal cancer with a very low overall 5-year survival rate. There is an urgent need for identifying new therapeutic agents for this deadly disease. Cardiac glycosides (CGs) have been traditionally used for their potent cardiovascular activities and have also recently been reported to exhibit anti-tumor effects. Proscillaridin A (Pro A), a natural CG, has been shown to display anti-tumor effects on multiple cancer types.
Methods
UNASSIGNED
The cytotoxic effect of Pro A on PC cells was determined using cell viability assay, colony formation assay and transwell assay
Results
UNASSIGNED
Pro A inhibits the proliferation, migration and invasion of Panc-1, BxPC-3 and AsPC-1 PC cells
Conclusions
UNASSIGNED
Our findings suggest that Pro A constitutes a promising therapeutic candidate for certain types of PC.
Identifiants
pubmed: 36034984
doi: 10.21037/atm-22-1085
pii: atm-10-15-820
pmc: PMC9403942
doi:
Types de publication
Journal Article
Langues
eng
Pagination
820Informations de copyright
2022 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-1085/coif). The authors have no conflicts of interest to declare.
Références
Molecules. 2017 Nov 08;22(11):
pubmed: 29117117
Int J Cancer. 2018 Aug 15;143(4):801-812
pubmed: 29524225
Cell Cycle. 2020 Mar;19(5):541-550
pubmed: 32009541
J Biol Chem. 2003 Aug 29;278(35):33571-82
pubmed: 12794086
Front Oncol. 2020 May 07;10:687
pubmed: 32457840
Int J Biol Sci. 2018 Jan 12;14(2):111-123
pubmed: 29483830
Br J Pharmacol. 2022 May;179(9):1874-1886
pubmed: 33665823
Prog Mol Biol Transl Sci. 2016;144:241-275
pubmed: 27865459
Gut. 2012 Nov;61(11):1583-8
pubmed: 22184070
Oncol Rep. 2001 Jan-Feb;8(1):89-92
pubmed: 11115575
Front Pharmacol. 2020 Sep 04;11:01055
pubmed: 33013353
Nat Commun. 2019 Oct 21;10(1):4731
pubmed: 31636264
Biol Pharm Bull. 2006 Jul;29(7):1493-7
pubmed: 16819197
Expert Opin Ther Targets. 2007 Aug;11(8):1043-53
pubmed: 17665977
Genet Med. 2015 Jul;17(7):569-77
pubmed: 25356972
Semin Oncol. 2019 Feb;46(1):28-38
pubmed: 30638624
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):81
pubmed: 33444531
Drug Des Devel Ther. 2015 Jul 07;9:3529-45
pubmed: 26185420
Cell Death Dis. 2018 Jun 13;9(6):696
pubmed: 29899551
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033819895494
pubmed: 32336215
Pancreas. 2004 Oct;29(3):193-203
pubmed: 15367885
Int J Biochem Cell Biol. 2012 Nov;44(11):1813-24
pubmed: 22750415
Crit Rev Oncol Hematol. 2017 Jun;114:139-152
pubmed: 28477742
Oncogene. 2018 Aug;37(32):4372-4384
pubmed: 29743592
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Virchows Arch. 2001 Dec;439(6):798-802
pubmed: 11787853
Pancreas. 2010 May;39(4):425-35
pubmed: 20418756
J Cell Physiol. 2016 Dec;231(12):2570-81
pubmed: 26895995
Free Radic Biol Med. 2011 Oct 1;51(7):1365-75
pubmed: 21763418
Pharmacol Ther. 2016 Dec;168:29-42
pubmed: 27595930
Cells. 2021 Nov 28;10(12):
pubmed: 34943848
Nat Rev Cancer. 2017 Sep;17(9):528-542
pubmed: 28751651
Mol Cancer. 2019 Dec 1;18(1):173
pubmed: 31785619
Cancer Causes Control. 2015 Nov;26(11):1583-91
pubmed: 26293241
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502
pubmed: 34002083
Biochem Pharmacol. 2014 May 15;89(2):197-209
pubmed: 24630927
BMC Cancer. 2019 Nov 4;19(1):1037
pubmed: 31684910
Pancreas. 2000 Aug;21(2):152-7
pubmed: 10975709
Int J Med Sci. 2018 May 22;15(8):832-839
pubmed: 30008594
Acta Biochim Biophys Sin (Shanghai). 2021 Jan 12;53(1):19-28
pubmed: 33201987
J Exp Clin Cancer Res. 2019 Jun 13;38(1):251
pubmed: 31196146
Cancer Cell. 2020 Aug 10;38(2):198-211.e8
pubmed: 32559497
Autophagy. 2019 May;15(5):796-812
pubmed: 30676840
Mitochondrion. 2013 May;13(3):225-34
pubmed: 22735572
Cancer Res. 2012 Sep 15;72(18):4840-5
pubmed: 22787119